Zofenopril – kardioprotekcja na każdym etapie kontinuum sercowo-naczyniowego Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Marcin Barylski

Abstrakt

Zofenopril jest lipofilnym, tkankowym inhibitorem konwertazy angiotensyny, który dzięki posiadaniu grupy sulfhydrylowej wywiera korzystny wpływ na śródbłonek, działa przeciwzapalnie, zwiększa lokalne wytwarzanie tlenku azotu i hamuje metaboliczne oraz hemodynamiczne efekty niedokrwienia mięśnia sercowego, co zwiększa kardioprotekcję na każdym etapie kontinuum sercowo-naczyniowego.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Barylski , M. (2017). Zofenopril – kardioprotekcja na każdym etapie kontinuum sercowo-naczyniowego. Kardiologia W Praktyce, 11(3), 25-28. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1245
Dział
Artykuły

Bibliografia

1. Filipiak K.J., Gąsecka A., Lewandowski M. et al.: Stosowanie inhibitorów konwertazy angiotensyny i diuretyków w leczeniu hipotensyjnym w praktyce polskich lekarzy – raport końcowy z badania ankietowego ALMONDS. Medycyna Faktów 2016; 9(1): 6-17.
2. Ranadive S.A., Chen A.X., Serajuddin A.T.M.: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 1992; 9: 1480-1486.
3. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons “in vitro”, “ex vivo”, and “in vivo” of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-131S.
4. Cushman D.W., Wang F.L., Fung W.C. et al.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypert. 1989; 2: 294-306.
5. DeForrest J.M., Waldron T.L., Krapcho J. et al.: Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 1989; 13: 887-894.
6. Mitchell G.F., Pfeffer M.A., Finn P.V., Pfeffer J.M.: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996; 94: 2923-2929.
7. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
8. Narkiewicz K.: Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. Suppl. 2007; 2: 7-12.
9. Mallion J.M.: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 13-18.
10. Borghi C., Cicero A.F.: Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vasc. Health Risk. Manag. 2006; 2(4): 341-349.
11. Brilla C.G.: Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc. Res. 2000; 46(2): 324-331.
12. Evangelista S., Manzini S.: Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 2005; 33: 42-54.
13. Liu X., Engelman R.M., Ronson J.A. et al.: Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 1992; 6: 437-443.
14. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
15. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148(1): e5.
16. Brogelli L., Parenti A., Capaccioli S. et al.: The angiotensin converting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis “in vitro”. FASEB J. 1999; 13: A528.
17. Ambrosioni E., Borghi C., Magnani B.: The Effect of the Angiotensin–Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. N. Engl. J. Med. 1995; 332: 80-85.
18. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. 2003; 145(1): 80-87.
19. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart J. 2007; 153(3): 445.e7-14.
20. del Corso F., Pareo I., Borghi C.: Evolving concept of cardioprotection in myocardial infarction: from SMILE-1 to SMILE-5. Kardiol. Pol. 2013; 71(7): 667-674.
21. Tykarski A., Narkiewicz K., Gaciong Z.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.